Aggressive Systemic Mastocytosis clinical trials at UCSF
1 in progress, 0 open to new patients
Sorry, not currently recruiting here
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase and an expansion phase.
San Francisco, California and other locations